Stock BIOSGN BIOSERGEN AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Biosergen AB

Equities

BIOSGN

SE0016013460

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 10:30:45 2024-04-26 am EDT 		5-day change 1st Jan Change
0.341 SEK +7.91% Intraday chart for Biosergen AB -15.17% -61.25%
Apr. 09 Biosergen to Issue New Units as Compensation Under Rights Issue MT
Mar. 27 Biosergen Raises SEK26.4 Million via Rights Issue MT

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025
Capitalization 1 152.3 44.55 44.6 48.55 -
Enterprise Value (EV) 1 152.3 15.21 44.6 111.7 336.4
P/E ratio -3.82 x - -1.66 x - -
Yield - - - - -
Capitalization / Revenue - 8.6 x - - 0.19 x
EV / Revenue - 2.93 x - - 1.31 x
EV / EBITDA - -0.38 x - -4.05 x 1.43 x
EV / FCF - - - - -
FCF Yield - - - - -
Price to Book - - - - -
Nbr of stocks (in thousands) 28,102 42,428 50,686 142,387 -
Reference price 2 5.420 1.050 0.8800 0.3410 0.3410
Announcement Date 3/31/22 3/31/23 2/29/24 - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023 2024 2025
Net sales 1 - 5.183 - - 257.3
EBITDA 1 - -39.99 - -27.6 235.6
EBIT 1 - -39.99 - -27.6 235.6
Operating Margin - -771.5% - - 91.57%
Earnings before Tax (EBT) - - - - -
Net income -34.32 - -27.04 - -
Net margin - - - - -
EPS -1.420 - -0.5300 - -
Free Cash Flow - - - - -
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 3/31/22 3/31/23 2/29/24 - -
1SEK in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 Q4 2023 Q1 2023 Q2 2024 Q1 2024 Q2
Net sales 1 1.964 5.315 2.456 - -
EBITDA 1 -12.49 -5.029 -8.038 -6.9 -6.9
EBIT 1 -12.49 -5.029 -8.038 -6.9 -6.9
Operating Margin -636% -94.62% -327.28% - -
Earnings before Tax (EBT) - - - - -
Net income - - - - -
Net margin - - - - -
EPS - - - - -
Dividend per Share - - - - -
Announcement Date 3/31/23 5/31/23 8/14/23 - -
1SEK in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025
Net Debt 1 - - - 63.1 288
Net Cash position 1 - 29.3 - - -
Leverage (Debt/EBITDA) - - - -2.286 x 1.222 x
Free Cash Flow - - - - -
ROE (net income / shareholders' equity) - - - - 105%
ROA (Net income/ Total Assets) - - - - 100%
Assets - - - - -
Book Value Per Share - - - - -
Cash Flow per Share - - - - -
Capex - - - - -
Capex / Sales - - - - -
Announcement Date 3/31/22 3/31/23 2/29/24 - -
1SEK in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
BIOSERGEN AB Stock Biosergen AB
-61.25% 4.43M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. BIOSGN Stock
  4. Financials Biosergen AB